Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + carboplatin intermittent chemotherapy versus gemcitabine + carboplatin in elderly advanced non-small cell lung cancer with chronic obstructive pulmonary disease
ChiCTR-IPR-15006164Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of docetaxel, carboplatin and gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Chest CT. Planned start Jan 2015; status: not yet recruiting.
02
Drugs
docetaxelcarboplatingemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IPR-15006164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006164.